Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study

Current Medical Research and Opinion
Wenying YangZhigang Zhao

Abstract

To explore safety and efficacy of BIAsp 30 as initiation or replacement therapy in routine clinical practice in patients with poorly controlled diabetes in the Chinese cohort of the IMPROVE study. In the 26-week, non-interventional, observational study, Chinese subjects with diabetes started BIAsp 30 treatment in routine care. Data from patients' diaries and medical records were transferred to CRFs by participating physicians. NCT00659282. Of the 21,729 subjects enrolled (mean age 54.0 years, BMI 24.6 kg/m 2 , diabetes duration 4.86 years), 32.3% were treatment-naïve, 59.3% were from oral anti-diabetic drugs (OADs) only and 8.1% were from insulin +/- OADs. Overall, mean HbA(1c) and FBG decreased by 2.82% and 5 mmol/L, respectively. In the subgroups, changes were: -3.27% and -6.06 mmol/L (treatment-naïve), -2.57% and -4.54 mmol/L (OADs only), -2.96% and 3.51 mmol/L (insulin +/- OADs) all p < 0.05. HbA(1c) < 7% was achieved by 71.4% of patients. Only 0.1% of subjects reported major hypoglycaemia and 73 SADRs were observed without significant difference compared to those at baseline. Body weight did not change significantly. Regardless of previous treatments, insulin initiation or replacement with BIAsp 30 improved glycaemic contr...Continue Reading

References

May 19, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·D R MatthewsR C Turner
Jan 27, 2005·Drugs·Andrew J Krentz, Clifford J Bailey
Apr 22, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·I F DouekUNKNOWN Metformin Trial Group
Mar 21, 2006·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Meryl BrodKim U Wittrup-Jensen
Sep 25, 2008·International Journal of Clinical Practice·P ValensiUNKNOWN IMPROVE Study Group Expert Panel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.